Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Achieved record 2025 revenue of $726.4 million, with GAAP gross margins of 79.4% and non-GAAP gross margins of 81.2%, the highest in company history.

• EXPAREL volume growth accelerated to 8% in H2 2025, nearly doubling H1, reflecting strong demand and commercial execution.

• Returned $200 million to stockholders since April 2025 under a $300 million share repurchase program.

• Advanced pipeline assets PCRX-201 and PCRX-2002, targeting large market opportunities in osteoarthritis and postsurgical pain.

• First quarter 2026 results showed sustained growth: EXPAREL revenue up 5%, ZILRETTA up 15%, iovera° up 21% year-over-year.

Voting matters and shareholder proposals

• Urges stockholders to vote “FOR” the election of the company’s nominees on the BLUE proxy card at the June 9, 2026 Annual Meeting.

• Opposes DOMA Perpetual Capital Management’s nominees, citing lack of relevant experience and misalignment with stockholder interests.

• DOMA’s plan includes replacing the CEO, cutting costs, discontinuing pipeline development, and pursuing an immediate sale of the company.

Board of directors and corporate governance

• Board composition would be 89% independent with an average tenure of 4.6 years after the Annual Meeting.

• Five new independent directors added since October 2023; a sixth nominated for election.

• Nominees bring approximately 70 years of biopharma experience and over 40 years of senior executive leadership.